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Abstract The human SLC6 family is composed of approxi-
mately 20 structurally related symporters (co-transporters) that
use the transmembrane electrochemical gradient to actively
import their substrates into cells. Approximately half of the
substrates of these transporters are amino acids, with others
transporting biogenic amines and/or closely related com-
pounds, such as nutrients and compatible osmolytes. In this
short review, five leaders in the field discuss a number of
currently important research themes that involve SLC6 trans-
porters, highlighting the integrative role they play across a
wide spectrum of different functions. The first essay, by Gary
Rudnick, describes the molecular mechanism of their coupled
transport which is being progressively better understood based
on new crystal structures, functional studies, and modeling.
Next, the question of multiple levels of transporter regulation
is discussed by Reinhard Krämer, in the context of osmoreg-
ulation and stress response by the related bacterial betaine
transporter BetP. The role of selected members of the human
SLC6 family that function as nutrient amino acid transporters
is then reviewed by François Verrey. He discusses how some of
these transporters mediate the active uptake of (essential) amino
acids into epithelial cells of the gut and the kidney tubule to
support systemic amino acid requirements, whereas others are
expressed in specific cells to support their specialized metabo-
lism and/or growth. The most extensively studied members of
the human SLC6 family are neurotransmitter reuptake trans-
porters, many of which are important drug targets for the treat-
ment of neuropsychiatric disorders. RandyBlakely discusses the
role of posttranscriptional modifications of these proteins in
regulating transporter subcellular localization and activity state.
Finally, Dennis Murphy reviews how natural gene variants and
mouse genetic models display consistent behavioral alterations
that relate to altered extracellular neurotransmitter levels.
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Introduction
The human SLC6 family contains evolutionary, and thus
structurally related, molecular machines that actively translo-
cate amino acids and related solutes into cells against their
concentration gradient using, as a driving force, the energeti-
cally favorable coupled movement of ion(s) down their trans-
membrane electrochemical gradients. All SLC6 members in-
deed transport one, two or three sodium ion(s) together with
their organic substrate (symport). Many of these transporters
additionally symport one chloride ion, and one transporter
also exchanges a potassium ion per substrate (antiport). The
SLC6 transporters are actually part of the larger neurotrans-
mitter sodium symporter (NSS) family of structurally related
transporters that includes numerous prokaryotic members, and
which itself is included in the very large amino acid–poly-
amine–organocation (APC) superfamily (Table 1) [26, 87].
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About half of the SLC6 family members transport amino
acids, of which some are neurotransmitters (glycine and
GABA) and the others transport related molecules such as
monoamine neurotransmitters (serotonin, norepinephrine,
and dopamine), creatine, or compatible osmolytes (taurine
and betaine).
In recent years, a number of excellent, systematic reviews
have presented extensive descriptions of the phylogenetic
organization of the SLC6 transporter family, focusing largely
on the literature published since the molecular identification of
its members began more than 20 years ago [8, 9, 43, 64]. The
purpose of the present review is to discuss, in a few essays,
several aspects of more current research, and to highlight
important questions likely to drive future studies, ranging
from the mechanistic structure–function relationship of
coupled transport to different aspects of transporter regulation,
and finally their role in neuropsychiatric disorders.
In the first essay, Gary Rudnick provides a conceptual
framework for part of the reaction cycle of SLC6 transporters
and discusses open questions regarding the transport mecha-
nism. The second essay addresses adaptation of transport
activity to changes in extracellular osmolarity as an important
property of a number of SLC6 family members transporting
compatible osmolytes. In this context, Reinhard Krämer em-
phasizes the central role played by post-translational trans-
porter processing for tuning the short term functional response
to stressful conditions, using the SLC6-related betaine trans-
porter BetP of Corynebacterium glutamicum as a model
Table 1 Classification of SLC6 family transporters
Transporter Classification Database (TCDB) (www.tcdb.org)
(based on sequence homology, includes prokaryotic and eukaryotic proteins)
Superfamily Acid–polyamine–organocation (APC) Second largest superfamily of secondary carriers
Family (within APC superfamily) Neurotransmitter sodium symporter family
(NSS)
One out of currently 10 families belonging
to APC superfamily
HGNC gene families/groupings nomenclature (www.genenames.org)
(nomenclature of human genome project, now used also for transporters of other eukaryotic genomes)
SLC gene nomenclature systema Solute carriers (SLC) Group of human gene families originally
proposed by the Human Genome Organization
(HUGO), comprising currently 52 SLC families
SLC family (within SLC group of gene
families)
Solute carrier family 6 (SLC6) Family including transporters with >20 %
sequence homology.
Themembers of SLC6 belong to the NSS family of
the TCDB classification
SLC6 subfamilies [8, 9, 43, 64] GABA transporters (= GABA,
neurotransmitter,
osmolyte, creatine transporters)
Subfamily includes:
SLC6A1, GAT1
SLC6A6, TauT
SLC6A8, CT1
SLC6A11, GAT3
SLC6A12, BGT1
SLC6A13, GAT2
Monoamine transporters (= monoamine
neurotransmitter transporters)
Subfamily includes:
SLC6A2, NET
SLC6A3, DAT
SLC6A4, SERT
Amino acid transporters (I) (= neurotransmitter
amino acid transporters)
Subfamily includes:
SLC6A5, GlyT2
SLC6A7, PROT
SLC6A9, GlytT1
SLC6A14, ATB0,+
Amino acid transporters (II) (= nutrient amino
acid transporters)
Subfamily includes:
SLC6A15, B0AT2
SLC6A16, NTT5
SLC6A17, NTT4
SLC6A18, B0AT3
SLC6A19, B0AT1
SLC6A20, SIT1
a The SLC gene nomenclature names are often used also for the corresponding transporters
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system. Next, the amino acid transporters of the SLC6 family
are briefly discussed by François Verrey who describes the
surprisingly broad spectrum of roles these active transporters
display. Whereas some transporters expressed at epithelial
surfaces mediate the first active uptake step of amino acids
into the organism, others import amino acids within the or-
ganism into cells either to control the extracellular concentra-
tion of their substrates, as it is the case for neurotransmitter
transporters, or to provide specific cells actively with amino
acids to be used for their specialized metabolism or growth.
Clearly, less information is available on amino acid trans-
porters than on neurotransmitter transporter of the SLC6 fam-
ily. This is due to their later molecular identification and to the
fact that unlike neurotransmitter transporters, they have not
been linked to important diseases, either by genetic associa-
tion or as drug targets.
The regulation of biogenic amine neurotransmitter trans-
porters of the SLC6 family and of their defects observed in the
context of neuropsychiatric disorders are discussed by Randy
Blakely, who emphasizes in his essay the role of post-
transcriptional modifications on transporter subcellular local-
ization and activity. In the last essay, Dennis Murphy dis-
cusses the role of SLC6 transporters in neuropsychiatric dis-
orders, in particular examples of genetic variants, pharmaco-
logical targets and corresponding mouse genetic models that
provide insights into the physiological and behavioral impact
of SLC6 neurotransmitter transporter alterations.
Mechanisms for coupled transport by SLC6 transporters
(Gary Rudnick)
Coupling of transport to ion gradients and potentials
The human SLC6 family is part of a larger NSS family of
homologous transporters that includes many prokaryotic
transporters. In turn, the NSS family is part of a superfamily
of structurally related transporters [26]. These proteins move
their substrates across the membrane using a variety of energy
sources. In many cases, transmembrane ion gradients provide
the driving force. Within the SLC6 family, substrates are
generally amino acids, although some family members trans-
port amines, such as the neurotransmitters serotonin (5-HT),
norepinephrine (NE), and dopamine (DA).
The ability of transporters in this family to concentrate their
substrates inside the cell depends on coupling the energetical-
ly favorable movement of Na+ and sometimes Cl− to the
energetically unfavorable flux of substrate into the cell
(symport). Because transport by these proteins is reversible,
the overall direction and magnitude of substrate transport is
determined by the polarity and strength of the ion and sub-
strate gradients. If electrical charge accompanies substrate
transport, the membrane potential can contribute to the driving
force, and some transporters additionally couple substrate
influx to the favorable efflux of K+ (antiport). By utilizing
the electrochemical potential in these ion gradients, SLC6
transporters can accumulate intracellular substrate to concen-
trations hundreds of times higher than outside the cell. The
coupling mechanisms responsible for this accumulation are
well documented but poorly understood at the molecular
level.
Alternating access models and rules for coupling
The physical model used to explain coupled transport (both
symport and antiport) is the alternating access mechanism
[59], which proposed two transporter conformations, each of
which exposes a central binding site to one side or the other of
the membrane (Fig. 1a). Interconversion of the two forms with
substrate bound allows substrate transport across the mem-
brane. However, to couple substrate and Na+ transport (for
example), this step should occur only when both substrate and
Na+ are bound. Then, after release of Na+ and substrate to the
cytoplasm, the transporter would revert to an outward-open
conformation with the binding sites empty. For strictly stoi-
chiometric Na+-substrate coupling, this mechanism requires
that the conversion between outward- and inward-open con-
formations should occur only when both Na+ and substrate are
bound or when the binding site is empty. For antiport, how-
ever, a counter-ion such as K+ and substrate must be
transported in different steps, and their binding should be
mutually exclusive. Substrate would be bound during the
transition from outward- to inward-open and K+ bound in
the opposite direction. In its strictest form, the alternating
access mechanism presumes that symported ions are bound
and transported together with substrate but antiported ions are
transported in the step when substrate is not bound (Fig. 1a).
Structures and models for SLC6 conformations
Any understanding of how transport is coupled to ion gradi-
ents requires that we understand the molecular details of
structure and conformational change. In the NSS family, there
is presently only LeuT, a prokaryotic amino acid transporter,
for which we have a high-resolution atomic structure. LeuT
has been crystallized in three conformations and with several
substrates and inhibitors. The first structures of LeuT were
with substrate bound and with the protein in an outward-
occluded conformation [89]. Subsequent structures showed
the protein in outward- and inward-open conformations [42].
The outward-occluded conformation is interesting and impor-
tant, because it provides a way for LeuT to transform from
outward- to inward-open forms without being simultaneously
open to both sides of the membrane. If the transporter opened
a pathway from the binding site to the cytoplasm before it
closed the pathway to the cell exterior, uncoupled flux of
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substrate and ions could occur. The presence of an intermedi-
ate state in which the binding site is effectively sealed off from
both sides prevents this uncoupled flux.
The first LeuT structure revealed an unexpected structural
motif that has since become a common feature in transporter
structures. In this 12-transmembrane (TM) helix protein, the
structure of TMs 1–5 is repeated in the structure of TMs 6–10
except that the topological orientation of the two similar struc-
tures is inverted. If the two repeats were identical, the overall
structure of TMs 1–10 would be symmetrical, but this was not
found. Instead, the extracellular substrate permeation pathway
in this occluded structure was open up to (but not including) the
central binding sites for Na+ and substrate but the cytoplasmic
pathway was totally closed. This asymmetry resulted from
differences in the conformation of the two repeats that proved
to be a key to understanding conformational change [27].
The structure of LeuT TMs 1–10 can be divided into two
domains, a four-helix bundle (TMs 1, 2, 6, and 7) and a
scaffold (TMs 3–5 and 8–10), with the two repeats contribut-
ing equally to each domain. The four-helix bundle sits at an
angle to the scaffold, packing, in outward-oriented conforma-
tions, closely against the scaffold on the cytoplasmic side of
the binding site and separating from the scaffold on the
extracellular side to create the extracellular pathway (cartoon
version in Fig. 1b). Inmodels of the inward-open structure and
structures of other members of the superfamily, the tilt axis of
the bundle is reversed, suggesting a “rocking bundle” mech-
anism that closes the extracellular pathway and opens a path-
way between the binding sites and the cytoplasm [27, 86]. All
structures in the superfamily are consistent with conforma-
tional change involving movement of the bundle relative to
the scaffold, and with relatively little conformational change
within the scaffold [26].
Differences between inward-open structures and models
raise the issue of how conformational changes in SLC6 trans-
porters are propagated. To account for many observations
where opening of the extracellular pathway was observedwith
reciprocal closing of the cytoplasmic pathway (and vice
versa), we proposed that the long, unbroken helices of TMs
2 and 7 might serve to transmit conformational changes be-
tween the extracellular and intracellular halves within the
bundle [26]. However, the LeuT inward-open structure sug-
gests that the cytoplasmic pathway opens when the cytoplas-
mic half of TM1 swings away from the rest of the helical
bundle [42], possibly requiring an alternate mechanism for
coupling this event to closing the extracellular pathway.
Fig. 1 Alternating access mechanisms and LeuT. a Similar conforma-
tional changes could account for symport (left) and antiport (right) using
different rules. Prohibited conformational changes are indicated by a red
bar. b The reaction cycle of LeuT is initiated by binding of two Na+ ions
(upper left) followed by substrate binding (upper right). Conformational
changes to the occluded state and the inward-open state follow (right).
Dissociation of Na+ and substrate leads to the apo-state (lower left) which
can re-orient to the outward open form (left). c–e Binding sites for Na1
and substrate (c) and Na2 in outward-open (d) and inward-open (e)
structures. Na1 binding site residues and transmembrane helices are
numbered
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Ligand-induced conformational changes
As more transporter structures are solved, the nature of con-
formational change in each transporter family is becoming
clearer, and knowledge of how ligand binding controls con-
formational change is becoming more important as the next
step in understanding the molecular mechanism of transport.
The rules that ensure strict coupling between ion and substrate
transport determine when the transporter changes conforma-
tion from inward- to outward-open. These conformational
changes occur only when a specific set of conditions are
satisfied. In the case of Na+-substrate symport, for example
by LeuT, the coupling between Na+ and substrate movements
requires that the conformational changes occur either when
the transporter has bound both Na+ and substrate or when
those binding sites are empty (Fig. 1a–b). Another way to
view these rules is that they prevent conformational change
when only Na+ or only substrate is bound. To accomplish this
discrimination, the protein must use binding site occupancy to
control conformational transitions.
For SLC6 transporters, the best structural model at present
is LeuT, and studies with LeuT and other transporters already
hint as to how SLC6 proteins accomplish the coupling of
binding to conformational change. The rocking bundle hy-
pothesis predicts that conformational changes occur by move-
ment of the four-helix bundle relative to the scaffold domain.
The point at which these two domains have the most consis-
tent contact is a nexus of binding sites for two Na+ ions and
one substrate molecule near the center of the protein (Fig. 1b–
c). Thus the structure is optimized to directly couple binding
site occupancy to conformational change.
In LeuT, and in the aromatic amino acid transporter Tyt1,
evidence suggests that Na+ influences conformational change.
Cysteine residues in the cytoplasmic pathway of Tyt1 were
less accessible in the presence of Na+, indicating a shift to an
inward-closed (outward-open) conformation [65]. Similar re-
sults for LeuT were observed using single molecule FRET
techniques, which also suggested that the cytoplasmic path-
way was closed by Na+ [90]. EPR measurements of accessi-
bility and distance in the LeuT extracellular pathway also
show changes with Na+, but because the EPR probes were
in the extracellular pathway, Na+ was found to increase acces-
sibility and distances between positions, consistent with the
extracellular pathway opening as the cytoplasmic pathway
closed [16]. From the results with Tyt1 and LeuT, substrate
causes the extracellular pathway to close and the cytoplasmic
pathway to open, but only in the presence of Na+.
These basic observations illustrate a mechanism that SLC6
transporters could use to couple Na+ and substrate transport.
The rules for symport prevent conformational change when
only Na+ is bound, and the ability of Na+ to stabilize one
conformation could lock the transporter in that outward-open
state until substrate binds. Indeed, both smFRET and EPR
show apo-LeuT distributed between inward- and outward-
open states in the apo-state but strongly biased by Na+ toward
outward-open conformations with transitions between states
largely eliminated [16, 90].
What prevents SLC6 proteins from transporting substrate
in the absence of Na+? Substrate binding by some transporters
in this family depends on Na+ [72]. This strong dependence
means that the substrate is unlikely to bind to apo-LeuT. These
observations provide a way for SLC6 transporters to prevent
transport of Na+ or substrate alone, but they do not indicate
how these rules ensuring strict symport are encoded in the
structure.
In LeuT structures, one of the two bound Na+ ions (Na1) is
directly coordinated by the substrate carboxyl group [89]. The
strong ionic interaction between Na1 and substrate forms an
essential part of the substrate binding site (Fig. 1c) and is
likely responsible for the Na+-dependence of substrate bind-
ing. The other bound Na+ ion (Na2) is bound at a site formed
by TM1 (in the four-helix bundle) and TM8 (in the scaffold)
[89] (Fig. 1d). The location of Na2 at this interface provides a
mechanism bywhichNa+ can stabilize the outward-open form
of LeuT. Occupation of the Na2 site could foster interaction
between the scaffold and the cytoplasmic half of the bundle,
closing the cytoplasmic pathway by holding the two domains
together [42]. In inward-open structures and models, by con-
trast, the Na2 site is not occupied and the two domains
separate from each other [27, 42] (Fig. 1e). Thus, specializa-
tion of the two Na+ sites, with Na2 serving to stabilize the
outward-open conformation and Na1 required for substrate
binding may hold the key to coupling between ion and sub-
strate transport.
The mechanism outlined above provides a conceptual
framework for part of the reaction cycle. Na+ binding initiates
the process, and the strong bias toward an outward-open
conformation prevents transport of the Na+ ions before sub-
strate binds. However, solid experimental validation is still
lacking. Moreover, substrate binding must trigger conforma-
tional change by overcoming the conformational effect of Na+
binding. Substrate binding in the extracellular pathway was
proposed to initiate this conformational change [72], but this
proposal has encountered resistance, in part because substrate
binding at the proposed site has not been observed in crystal
structures. Alternative mechanisms have not been proposed,
however, and the effect of substrate on conformational change
remains an unresolved topic for future studies.
Although amino acid substrates cannot bind in the absence
of Na+, amine neurotransmitters such as 5-HT, DA and NE do
not have carboxyl groups and do not require Na+ for binding.
It is still not clear how an SLC6 amine transporter would
prevent substrate transport in the absence of Na+.
Furthermore, transporters for 5-HT and NE are likely to
symport only one Na+ ion with substrate [37, 79], despite
conservation of both Na1 and Na2 sites. An aspartate in
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TM1 unique to these three amine transporters is now known to
participate in coordinating Na1 in the Drosophila DA trans-
porter [60]. It is likely that this aspartate replaces the missing
substrate carboxyl group in SLC6 amine transporters,
allowing the transporter to hold on to Na1 through the trans-
port cycle when it releases Na2 and substrate to the cytoplasm.
The role of SLC6 transporters in osmoregulation
and stress response (Reinhard Krämer)
Stress response is a vital aspect of cellular life, both in pro-
karyotes and in eukaryotes. Among various types of environ-
mental stress, a change in the external osmolality is a frequent
type of challenge. The cell’s response to this challenge is
called osmoregulation in prokaryotes and volume control in
eukaryotic cells. Although the long-term adaptation to these
conditions at the level of transcription, translation, and post-
translational processing are also relevant to the response, the
contribution of acute regulation of transport system activity is
the main focus when considering the stress response.
The activity of several transporters in the SLC6 family has
been proven or is assumed to be modulated by a change in the
osmolality of their surroundings. Relevant examples are Bgt1,
TauT, and SNF-12 [9, 20]. The best-studied models for osmo-
regulation are members of the structurally related BCCT
family of transporters, named after the typical substrates be-
taine, carnitine, and choline [95]. One member of this family,
the betaine transporter BetP from the Gram-positive soil bac-
terium Corynebacterium glutamicum , is a paradigm for regu-
lated secondary transport [95]. Consequently, the major lines
of interest and research perspectives will be outlined using this
carrier as a basis.
BetP is a secondary transporter composed of 595 amino
acids, 12 transmembrane segments, and prominent N- and C-
terminal domains, which are critically involved in sensing
osmotic stimuli [58, 62]. It exclusively accepts glycine betaine
as a substrate. Active uptake of betaine is coupled to co-
transport of two Na+ ions and thus driven by the electrochem-
ical Na+ potential [23]. As a particular feature, BetP comprises
two independent functions: It catalyzes active transport of
betaine, and it senses physical stimuli related to hyperosmotic
stress which lead to activation of the transporter. Detailed
biochemical and structural information on BetP is available,
covering both the functional analysis of catalytic activity
(transport) as well as regulation (stimulus sensing and signal
transduction), and in depth structural analysis on the level of
2D and 3D crystals [61, 68, 95]. Consequently, BetP is a
prominent example where the integration of biochemistry
and structural biology has led to deep insight into the mech-
anism of both transport catalysis and transport regulation. A
detailed picture for the catalytic cycle of BetP is available
based on the observation of several different crystal forms of
this protein representing different conformational states within
the transport cycle [61]. Stimulus analysis has shown that
BetP activity is modulated by two different types of physical
stimuli. A rise in internal K+ is the immediate cellular response
to a hyperosmotic shift and has been proven to be a primary
stimulus mainly based on results using purified reconstituted
BetP [69]. Very recently, by detailed analysis under in vivo
conditions, a second type of stimulus was discovered to be
required, in addition to K+, for full activation of BetP. This
stimulus is a change in the physical state of the membrane
directly surrounding BetP (unpublished results).
Despite the fact that a wealth of functional and structural
information regarding its response to osmotic stress is already
available for BetP, there are a number of urgent and interesting
questions, based on the rather advanced state of our knowl-
edge of mechanistic aspects available for this transporter.
Since BetP is a molecular machine integrating transport catal-
ysis, stimulus perception, signal transduction and stress adap-
tation all in one single polypeptide chain, it is compelling to
obtain a precise description of the sequence of these events at
the level of domain function and peptide chain movements.
On the basis of detailed structural work, we have a compara-
tively good insight into the conformational events in the core
domain of BetP according to the mechanism of alternative
access [61]. This is, unfortunately, not the case for stimulus
sensing and intramolecular signal transduction. Moreover,
BetP is a rare example of a transporter, for which the physical
stimuli modulating its catalytic action are at least partly un-
derstood. However, the mechanistic picture is far from com-
plete, and I would like to illustrate this for a physiologically
relevant situation.
Stress response is not a simple sequence caused by the
action of a stimulus and resulting in an immediate reaction
of the target protein. In order to guarantee proper survival, the
cell needs to adapt its response in a graduatedmanner, a higher
extent of stress leading to a stronger reaction and a lower
extent leading to a more moderate response. In fact, BetP
was shown to behave exactly like this [7]. Its action, betaine
uptake, ceases at an appropriate level of betaine accumulation
when osmotic compensation is reached (Fig. 2). This physio-
logically meaningful behavior raises at least two questions.
How does BetP accurately sense when betaine uptake should
stop, in spite of continuing high osmolality of the external
medium and, in particular, in spite of the fact that the stimulus
for activation, internal K+, continues to be high for prolonged
periods under these conditions? Notably a graduated response
to an external stress-related stimulus is more complex than a
graduated response in transport activity due to substrate avail-
ability, for example, which is simply mediated by variable
saturation of the substrate binding site. The second question
does not directly refer to molecular details of regulating pro-
tein activity by external stimuli, but rather asks more funda-
mentally: Is regulation on the level of the individual BetP
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molecule or the population? A perfectly adapted BetP, fine-
tuned to the actual extent of osmotic stress can be achieved
either by a sophisticated molecular mechanism leading to a
graduated response of every single BetP molecule or by a
balanced steady state of individual BetP molecules oscillating
between active and inactive states. Although we intuitively
tend towards the latter explanation, the answer to this question
is by no means clear and has not been achieved for any
regulated transport system.
The aim of the question(s) raised is to explain fine-tuned,
physiologically relevant responses of transporters on a mech-
anistic level or, in other words, to gain full mechanistic un-
derstanding of the regulatory and catalytic action of a trans-
porter in a physiologically relevant context. What are the tools
required to reach this aim? On amacroscopic level, we need to
challenge results obtained by biochemical and/or structural
biology approaches, frequently in a simplified experimental
setup, by checking their validity under in vivo conditions in
intact cells to the extent possible. In the case of BetP, as an
example, the specific stimulus of high luminal K+ concentra-
tions was identified. However, the fact that BetP activity in
intact cells down-regulates during osmotic adaptation despite
continuing high internal K+ led us to propose and finally
identify a second type of stimulus, which seems to be relevant
for this mechanism of adaptive fine-tuning. On a microscopic
level, we need a couple of additional tools in order to be able
to solve questions of the quality raised above. High resolution
3D structures are truly a tremendous help for interpreting
transporter function, however, they probably will not provide
appropriate answers to some of the functional questions de-
scribed above. Various spectroscopic techniques, particularly
fluorescence spectroscopy, as well as EPR and NMR, are
instrumental for responding to the challenges in understanding
the dynamic properties of membrane proteins. Only with
successful application of single molecule techniques, com-
bined, for example, with FRET analysis, we will be able to
resolve questions regarding the mechanistic basis of the per-
fectly fine-tuned response by this type of proteins to external
stress conditions in physiologically relevant surroundings.
Concentrative amino acid uptake transporters: cellular
and systemic roles (Francois Verrey)
SLC6 amino acid transporters
Approximately half of the SLC6 family genes encode amino
acid transporters that are phylogenetically grouped in two
subfamilies (I and II). Their common function is the concen-
trative cellular uptake of proteinogenic amino acids which is
driven by the symport of at least one Na+ ion down its
electrochemical gradient. However, these transporters differ
in terms of amino acid substrates, localization, co-transport
stoichiometry and functional roles. As discussed below, these
SLC6 amino acid transporters are involved in three different
functions each requiring concentrative cellular uptake: (1)
control of the extracellular concentration of neurotransmitter
amino acids in the context of synaptic transmission (transmit-
ter reuptake); (2) active uptake of amino acids into specific
cells to support their specialized metabolism or growth and/or
(3) active epithelial uptake of amino acids from the lumen of
the gut and kidney tubule to support systemic amino acid
requirements.
The first of the two SLC6 amino acid transporter subfam-
ilies is called amino acid transporters (I) or amino acid neuro-
transmitter transporters and includes GLYT1 and GLYT2
(SLC6A9 and SLC6A5), PROT (SLC6A7), and ATB0+
(SLC6A14) [9, 64]. The first three members of this subfamily
appear indeed to play a role in the modulation of synaptic
transmission, whereas ATB0+ (SLC6A14) has quite different
functions. The GLYTs function as high affinity transporters
(KM in 10–100-μM range) for glycine. GLYT2 (SLC6A5)
was suggested to function mostly as neuronal reuptake trans-
porter for the inhibitory neurotransmitter glycine with a high
driving force (3 Na+/1Cl−/glycine co-transport). It localizes to
glycinergic nerve terminals where it keeps extracellular gly-
cine levels low and displays highest expression in the brain
stem, cerebellum and spinal cord [48]. GLYT1 (SLC6A9) is
expressed as several isoforms with different localizations and
functions and its driving force for glycine uptake is somewhat
lower with a co-transport stoichiometry of 2 Na+/1Cl−/gly-
cine. In the central nervous system, it has been suggested to
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Fig. 2 Fine-tuning of BetP-mediated betaine uptake. Upon a
hyperosmotic upshift (A >B) which leads to an increase in the cytoplas-
mic K+ concentration, BetP switches into the active state and actively
accumulates betaine in the cell.When osmotic adaptation is reached, BetP
activity ceases (B >C). Upon application of a second upshift to higher
external osmolality (C >D), the cycle of activation and adaptation (C >D ,
D>E) is initiated again
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localize to glial cells and to modulate the effect of glycine on
NMDA receptor-mediated glutamatergic transmission. In ad-
dition, it appears to play a role in cellular glycine uptake in
cells of various organs. The third member of this SLC6
subfamily is PROT (SLC6A7), a L-proline transporter with
a KM value of about 10 μM that also transports a number of
other amino acids and compatible osmolytes at physiological-
ly relevant concentrations. It has been shown to be electro-
genic, inhibited by enkephalins and expressed essentially only
in brain. There it is localized mainly to synaptic vesicles of
some glutamatergic nerve terminals where it is suggested to
play a modulatory role. The fourth member of this subfamily
has a surprisingly different function, as it appears to be the
concentrative amino acid transporter with the broadest selec-
tivity range and to lack expression in the brain. It indeed
transports all neutral and cationic proteinogenic amino acids
with a relatively high apparent affinity (KM for essential
amino acids in the 10–100-μM range) and is expressed in
oocytes, large intestine and lung epithelia [74]. In view of its
ability to transport all essential and most non-essential amino
acids, it is not surprising that it is expressed in a large number
of different cancers and corresponding cell lines [35].
The second of these two SLC6 subfamilies has been called
amino acid transporters (II) or nutrient amino acid trans-
porters. Looking at its phylogenetic tree one may actually
divide this subfamily into two groups, one including B0AT2
(SLC6A15), NTT4 (SLC6A17), and the orphan transporter
NTT5 (SLC6A16) and a second including SIT1 (SLC6A20),
B0AT3 (SLC6A18), and B0AT1 (SLC6A19). Two trans-
porters of the first group, B0AT2 (SLC6A15) and NTT4
(SLC6A17), appear to be expressed mostly in neurons of the
brain and eye and additionally also in some other organs. They
display similar amino acid selectivity, B0AT2 transporting for
instance branched chain amino acids, L-methionine and L-
proline with a KM in the range of 40–200 μM and some other
neutral amino acids with a KM in the mM range. Both of these
transporters were also proposed to co-transport amino acids
and Na+ with a 1:1 stoichiometry [10]. In contrast, the quite
closely related SLC6A16 transporter is still an “orphan”.
Unlike B0AT2 and NTT4, it is expressed in some peripheral
tissues, particularly in testis, pancreas, and in the prostate.
Transient transfection experiments suggested it was localized
intracellularly.
The second group within the nutrient amino acid transport-
er subfamily is composed of three transporters which are
mainly expressed at the luminal membrane of epithelia that
specialize in amino acid uptake and thus mainly subserve a
crucial role for the systemic intake of amino acids and thus
metabolic homeostasis. The uptake of amino acids from the
environment is indeed a highly conserved function of the
larger NSS family of transporters that includes the metazoan
SLC6 transporters and also procaryotic transporters such as
for instance LeuT. Unlike in bacteria, amino acids taken up
from the environment by metazoa need to traverse at least
three membranes to reach their intracellular site of use: (1)
uptake into an epithelial cell at the surface of the organism
(i.e., luminal side of gut mucosa), (2) basolateral efflux from
the epithelial cell into the extracellular space (milieu intérieur)
and then uptake into another (somatic) cell. SLC6 transporters
are indeed potentially mediating the uptake steps (1) and (3)
using the transmembrane electrochemical gradients of sub-
strates and co-transported ions as a driving force. In contrast,
the efflux step (2) is mediated by uniporters and antiporters
belonging to other SLC families.
From the three mammalian SLC6 transporters expressed at
the surface of epithelial cells, only two have retained an active
function in humans: the main low apparent affinity (KM in
millimolar range) broad selectivity neutral amino acid trans-
porter B0AT1 and the higher affinity (KM about 100 μM) L-
proline transporter SIT1. In contrast, the B0AT1-related trans-
porter B0AT3 (SLC6A18), which, in rodents, transports neu-
tral amino acids with a higher apparent affinity in the later
segments of kidney proximal tubule, appears to have no
relevant functional role anymore in human, as a frequent
single-nucleotide polymorphism encodes a stop codon [73].
The broad selectivity transporter B0AT1 (SLC6A19) is the
main luminal neutral amino acid transporter in the small
intestine and in the kidney proximal tubule. Interestingly, this
transporter needs association with the membrane-anchored
peptidase ACE2 for its expression at the brush border surface
membrane of intestinal enterocytes, where it was shown to be
included in a digestive complex [12, 21]. In the absence of
ACE2, B0AT1 protein appears to be absent from the intestinal
mucosa, presumably due to its rapid ER-associated degrada-
tion [12]. Why B0AT1 in kidney proximal tubule does not
associate with ACE2 expressed in the same cells is not yet
known. Instead, in these cells, B0AT1 requires association
with collectrin (TMEM27) to reach the plasma membrane.
In the absence of this transmembrane protein, which is struc-
turally related to ACE2 but lacks the peptidase domain, kid-
ney proximal tubule B0AT1 is rapidly degraded [19].
Interestingly, it appears that the related transporter SIT1 re-
quires the same partners for its expression at the surface of
small intestine and kidney proximal tubule.
Uptake of essential amino acids
The cellular uptake of essential amino acids, in particular of
branched chain and aromatic amino acids, is important for
supporting cell growth and specific metabolic tasks. This
requires the expression at the cell surface of transporters that
import these amino acids. Interestingly, the small number of
transporters known to fulfill this task belongs to three different
mechanistic categories, uniporters, antiporters and
symporters. It appears, however, that the uniporters, TAT1
(SLC16A10) or LAT3 (SLC43A1) and LAT4 (SLC43A2)
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(Fig. 3a), are not able to support rapid growth and/or high
metabolic demand, because they can only equilibrate the
concentration of essential amino acids across the membrane
and do not actively concentrate them inside the cell. In con-
trast, the heterodimeric amino acid antiporter (exchanger)
LAT1-4F2hc (SLC7A5-SLC3A2) is well known for its im-
portant role in the context of growth. This transporter and also
LAT2-4F2hc (SLC7A8-SLC3A2) can indeed transport all
essential neutral amino acids in exchange for other amino
acids. Thus they can accumulate essential amino acids in the
cells by taking advantage of the high intracellular concentra-
tion of free amino acids (tertiary-active transport, see Fig. 3b),
providing the cell contains high amounts of non-essential
efflux substrates for driving their uptake. It is probably be-
cause of this capability of LAT1-4F2hc to accumulate essen-
tial amino acids that a very large number of cancers express it
[57]. From the third mechanistic category, symporters that
cotransport amino acids with ions, as yet only two are known
to actively transport branched and aromatic amino acids into
cells and interestingly both are members of the SLC6 family.
Other secondary-active amino acid transporters that also play
a major role for cell growth and metabolism, in particular
members of the families SLC36 (PATs) and SLC38 (system
A and N), do not transport branched and aromatic amino acids
but only small neutral ones. Thus cells expressing these
secondary-active transporters, for instance system A, depend
on the co-expression of one of the exchangers mentioned
above for the active uptake of essential large neutral amino
acids [82] (Fig. 3b). The two SLC6 amino acid transporters
actively transporting large neutral amino acids are ATB0+
(SLC6A14) and B0AT1 (SLC6A19). B0AT1 displays a low
apparent affinity for its substrates (KM in millimolar range)
and is expressed at the luminal surface of epithelial cells
(Fig. 3d). Interestingly, this transporter has not yet been found
to be associated with cancer, in contrast to the high apparent
affinity (KM in micromolar range) essential amino acid trans-
porters LAT1-4F2hc and ATB0+ possibly due to its low ap-
parent affinity for amino acids. The broad selectivity amino
acid transporter ATB0+ (SLC6A14) (Fig. 3c), which accom-
modates both neutral and cationic amino acids, has a much
higher apparent affinity for amino acids, particularly for es-
sential ones (KM in μM range), than B
0AT1 (KM in mM
range) [74]. ATB0+ had originally been characterized as trans-
port activity in blastocytes and the transporter has been shown
to be expressed also in oocytes, colon, lungs and other organs.
As mentioned above, like LAT1-4F2hc, it is also highly
expressed in a number of cancers, in particular, cancers of
colorectal and breast origin [35].
Open questions
This short section highlights the fact that the SLC6 amino acid
transporters are secondary active and thus concentrative up-
take transporters and briefly describes their differential func-
tions in the context of neurotransmission, cell growth/
metabolism or epithelial transport. Many different questions
regarding these transporters need to be addressed, in particular
because of the strong link between nutrient transport and
cellular metabolism and their important physiological and
pathophysiological roles. Very little is known about the cell-
specific expression and regulation of SLC6 amino acid trans-
porters at the level of expression and function. Because of
their overlapping amino acid selectivity, their differential ki-
netic properties and their interdependence for maintaining
cellular and systemic amino acid homeostasis, more system-
atic work also involving modeling will be required to bring
our understanding to a higher level.
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Fig. 3 Cellular uptake of essential amino acids (EAAs). Only a small
number of transporters mediate the uptake of essential amino acids.
Uniporters, as shown in panel a , equilibrate the concentration of aromatic
or branched chain EAAs across the plasma membrane. Panel b shows a
heterodimeric antiporter (obligatory exchanger) that can exchange
intracellular amino acids (e.g., non-essential amino acids (NEAAs) taken
up by other transporters) against extracellular EAAs (tertiary-active trans-
port). Panels c and d (epithelial cell) show the only two symporters
known to actively import EAAs into cells using the driving force of ion
gradients (secondary-active transport)
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Modulation on the move: a perspective on the regulation
of monoamine neurotransmitter transporters (Randy D.
Blakely)
Even before their cloning, neuroscientists speculated that the
regulation of neurotransmitter transporter expression and
function could contribute to the plasticity characteristic of
neuronal synapses, contributing ultimately to changes in be-
havior [52, 84, 85]. The availability of molecular tools in the
early 1990s provided opportunities to put these speculations to
the test [2]. Over the past 20 years, members of our field have
shown that transporters undergo reversible phosphorylation,
that activation of intracellular signaling pathways can influ-
ence transporter trafficking, that transporters reside in mem-
brane microdomains where mobility, function and drug re-
sponses can bemodulated, and that transporters associate with
many kinds of proteins, from other membrane proteins, to
cytoskeletal adaptors, to enzymes, that regulate their availabil-
ity and actions [6]. As emphasized below, even a brief com-
mentary on the field reveals both remarkable progress, yet so
much to be done. This is particularly the case in the effort to
transfer the findings of the past decades from in vitro model
systems and, for the most part, non-physiological stimuli, to
studies of transporter regulation by behaviorally relevant trig-
gers in vivo. As space does not permit the depth of citation
characteristic of a comprehensive treatment, the reader seek-
ing to pursue these topics in depth should consider examina-
tion of a number of more comprehensive reviews [6, 43, 67,
75]. This review will focus on the regulation of biogenic
amine neurotransmitter transporters, proteins that are respon-
sible for dopamine (DA), norepinephrine (NE), serotonin (5-
HT), and choline (Ch) transport [dopamine transporter (DAT),
norepinephrine transporter (NET), serotonin transporter
(SERT), and CHT, respectively], with which this author is
most familiar. It is likely that the same general conclusions
would apply, for example, to glutamate, γ-aminobutyric acid
(GABA), or glycine transporters.
Transporter phosphorylation
A major advance with respect to biogenic amine transporter
regulation came with the demonstration that all neurotrans-
mitter transporters examined to date can be phosphorylated in
response to activation of intracellular signaling pathways,
with the most detailed findings arising from studies of path-
ways subserved by Ser/Thr protein kinases, including protein
kinase A (PKA), protein kinase C (PKC), protein kinase G
(PKG), mitogen-activated protein kinases such as ERK and
p38 MAPK, Ca2+/calmodulin-linked protein kinase II
(CamKII) [29, 67]. These studies have now been advanced
to the state where all of the biogenic amine transporters have
been documented to be, through one manipulation or another,
phosphorylated in natively expressing tissue preparations or
cultured cells. It was clear at the outset of the cloning era that
biogenic amine transporters possesses multiple potential phos-
phorylation sites, but, up to this point, only a few of these sites
have been convincingly identified and linked to a specific
function. Indeed, studies from the Gether lab [36] revealed
that a DAT truncation that drastically reduced PKC-dependent
phosphorylation of DAT failed to alter transporter endocytosis
following PKC activation, a behavior considered by many up
to that point (including this author) to likely derive from direct
transporter phosphorylation. That’s not to say that progress
has not been achieved. Vaughan’s group has fingered a num-
ber of N-terminal residues in the phosphorylation of DAT that
can influence transport function and drug responses (e.g.,
[30]) with evidence provided, interestingly enough, for phos-
phorylation associated with trafficking -independent actions
of PKC activation [28]. Ramamoorthy’s team convincingly
demonstrated that activation of PKG-linked SERT trafficking
to the cell surface derives, at least in transfected cells, from
phosphorylation of Thr276 [66], whereas Annamalai and
colleagues implicated Thr258 and Ser 259 in NET in PKC-
dependent endocytosis of NET [3]. Also, Khoshbouei et al.
have shown that N-terminal Ser residues are critical for am-
phetamine (AMPH)-induced DA efflux, sites now believed to
be targeted by CamKII [25]. A major caveat to all of these
studies, and a key step for the field in the future, is the
demonstration that these sites are modified in vivo by physi-
ologically relevant stimuli and are responsible for behavioral-
ly meaningful regulation of transporters at synapses. It would
be exciting to see the same phosphopeptide antibody-mass
spectrometry approaches that have been used successfully to
implicate specific sites of phosphorylation of DAT in synap-
tosomes [30, 53] applied to tissue from animals receiving
in vivo drug or behavioral challenges. Recently, Pizzo and
colleagues [63] used the expression of human DATmutants in
Drosophila, followed by activity monitoring, to gather evi-
dence that the N-terminal Ser residues of DAT proposed to be
CamKII targets are required for the hyperlocomotory actions
of AMPH in vivo. Important next steps in this story are
parallel demonstrations of changes in DA efflux to validate
the proposed impact of DAT mutations in vivo and a demon-
stration that targeting of these sites and DA efflux (versus
competition for DA uptake) is critical for the behavioral
actions of AMPH on DAT [18]. Additionally, our current
specification of kinases and phosphatases that support trans-
porter phosphorylation do not distinguish between direct and
indirect actions (i.e., one kinase modifying another, which
ultimately phosphorylates the transporter). Methods such as
that recently introduced by Rudnick’s group in demonstrating
that, at least in vitro, PKG does not appear to phosphorylate
SERT directly, need to be more extensively incorporated into
our efforts [88]. We also need to move to the use of models
featuring reversible modifications of specific phosphorylation
sites that could allow for timed generation or elimination of
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phosphorylation, since constitutively engineered modification
of coding sites in transgenic animals can introduce significant
compensatory issues. We and others are presently exploring
the use of conditional knock-in strategies [71], but approaches
where the use of drugs or peptides that could reversiblymask a
phosphorylation site after systemic or local injection in vivo
also seem worth considering.
More broadly, we lack an understanding of how intracel-
lular signaling pathways, particularly those activated by en-
dogenous receptors, converge to achieve proper temporal and
spatial control of neurotransmitter action. We recently dem-
onstrated that p38 MAPK-dependent hyperphosphorylation
arises in an autism-associated mutation of SERT (Ala56)
assessed in a mouse knock-in model, leading to constitutively
elevated 5-HT clearance, and behavioral perturbations charac-
teristic of the disorder [81]. But how this pathway is naturally
triggered to regulate SERT, possibly through activation of
inflammatory cytokine signaling, is only now coming into
focus [5, 94]. Since biogenic amine transporter coding varia-
tion is rare, the definition of signaling pathways that lead to
disease-associated transporter phosphorylation, as well as oth-
er regulatory, post-translational modifications (e.g.,
ubiquitylation, palmitoylation), will likely be key to establish-
ing the impact of these changes on disease processes. Growing
evidence supports the existence of physical and/or functional
interactions of presynaptic receptors with neurotransmitter
transporters [46, 93], providing opportunities for both
autoreceptor and heteroreceptor regulation of neurotransmitter
uptake. The possibility that disrupted receptor–transporter
interactions underlie risk for neuropsychiatric disorders seems
plausible and should be given further consideration [13, 45].
Transporter trafficking to sites of functional expression
Biogenic amine transporters, like all membrane proteins, must
reach plasma membrane after passage through the endoplas-
mic reticulum (ER) and Golgi. Neurons feature highly com-
plex processes within which membrane microdomains are
well known to support specialized functions (e.g., node of
Ranvier, synaptic junctions, dendritic spines). Very little is
known as to how neurotransmitter transporters reach these
specialized sites of expression. Three general pathways are
likely to support transporter export—the budding frim the ER
and intracellular movement of transporters to distal sites, the
targeting or lateral entry of transporters into the microdomains
of the plasma membrane, or the latter process coupled to
endocytosis and relocation of internalized transporters to other
sites.With respect to export from the cell soma, several studies
have implicated distinct isoforms of COPII Sec24 proteins in
the export of multiple neurotransmitter transporters from sites
of synthesis [22, 76]. These proteins appear to help bud and/or
traffic transporter-containing vesicles to sites where they can
engage cytoskeletal transport machinery (e.g., microtubules)
and thereby reach the cell surface. Studies to date, however,
derive from heterologously expressed transporters and we
may expect many nuances in this export mechanism as studies
move to a native context.
One model where such mechanisms may be readily evalu-
ated is C. elegans , which express orthologs of DAT, SERT,
and CHT. Matthies and colleagues [50] demonstrated that the
CHT ortholog CHO-1 is exported from the cell soma on
vesicles that rely on the kinesin motor protein UNC-104.
Interestingly, CHO-1 and the vesicular acetylcholine (ACh)
transporter (VAChT, UNC-17) are retained in the cell soma of
cholinergic neurons in unc -104 mutants. Although it is not
known if these two proteins move on the same vesicles,
evidence from mammalian studies indicates that they ulti-
mately can reside on the same vesicle where VAChT imports
ACh for release and where CHT resides to move to the plasma
membrane upon vesicle fusion [24]. Interestingly, studies by
McDonald and coworkers [51] indicate that the C. elegans
DAT ortholog (DAT-1) and the vesicular monoamine trans-
porter 2 (VMAT2) ortholog (CAT-1), do not traffic through
the same pathway to DA terminals as CAT-1 trafficking out of
the cell soma is blocked by the unc -104 mutation, whereas
DAT-1 is exported to DA synapses. The C. elegans model is
particularly attractive for future studies of native neurotrans-
mitter transporter export owing to the transparency of the
animal and the ease of transgenic expression of wild type
and mutant, fluorescently tagged transporters. In another facet
of the McDonald et al. study noted above, these authors
demonstrated a role for C-terminal sequences in the export
of DAT-1 to DA terminals. Possibly these sequences relate to
the aforementioned SEC-24 protein interactions. Interestingly,
DAT export to the synapse in the worm model is not depen-
dent on the type II PDZ domain interaction sequences on the
distal DAT C-terminus previously shown to be targeted by
PICK-1 [80]. Finally, SERT, NETand DAT proteins also exist
on dendritic membranes of 5-HT, NE and DA neurons, re-
spectively, where they appear to serve to regulate neurotrans-
mitter actions on firing-regulating autoreceptors (e.g., see
[56]). The long dendrites associated with CEP DA neurons
in the nematode model suggests that the worm model may
also be very useful in understanding mechanisms that support
the dendritic localization of neurotransmitter transporter
proteins.
Transporter membrane trafficking
With the development of biogenic amine transporter-directed
antibodies and fluorescent transporter fusions, investigators
began to pursue the regulated movement of these proteins to
and from the cell surface, as well as their localization to
membrane microdomains. As noted above, the first evidence
that biogenic amine transporter trafficking in or out of the
plasma membrane could be regulated came from studies
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monitoring the rapid relocation of surface transporters to
intracellular compartments following PKC activation. Over
the years, studies have shown that such regulation rests on
constitutive patterns of internalization and externalization that
can be monitored separately by biotinylation or by the use of
surface-epitope targeted antibodies. Melikian’s group [49] has
presented evidence that distinct C-terminal sequences of DAT
subserve constitutive vs PKC-modulated DAT trafficking.
Galli’s group [14] has shown that plasma membrane levels
of DAT proteins are also controlled by PI-3 kinase (PI3K)-
linked pathways, though whether endocytic or exocytic (or
both) facets of transporter recycling are modulated is un-
known. PKG-linked pathways support SERT insertion into
the plasma membrane [5], with evidence now available in
both native and transfected cell populations. CHT proteins
contain powerful endocytic sequences that are likely at work
to drive the bulk of CHT proteins being resident on choliner-
gic synaptic vesicles [24]. As with the challenges for the
future, and as noted for phosphorylation mechanisms, scant
information is yet available that demonstrates the engagement
of these trafficking pathways or its physiological relevance
in vivo. In this regard, the Chavkin lab established that that
raphe neuron p38 MAPK can modulate SERT availability
and, in so doing, support the aversive actions of delta opiates
[11].
Transporters in membrane microdomains
Over the past decade, multiple studies have established that
biogenic amine transporters reside at the cell surface within
membrane microdomains that are rich in cholesterol and the
ganglioside GM1 and that, for many, are designated somewhat
inappropriately as “lipid rafts”. Localization to these domains
appears to restrict transporter mobility [1, 15], likely due to
anchoring to cortical actin networks via a multitude of asso-
ciated proteins. Using a quantum-dot conjugated antidepres-
sant, we recently visualized natively expressed SERT in
RN46A cells in vitro, associated with such membrane micro-
domains, demonstrating at a single molecule level that lateral
mobility of the transporter is significantly lower than that of
transporters outside of these domains (Fig. 4) [15]. Although
wewere able to increase SERT protein mobility by cholesterol
extraction, as was previously demonstrated for DAT proteins,
it remains unclear whether biogenic amine transporters can
move in and out of membrane microdomains as a feature of
their regulation. One could envision departure from rafts
occurring via the departure and free diffusion of transporters
or via endocytosis and re-insertion into different compart-
ments of the plasma membrane. Presumably, either of these
models depends on reversible associations with transporter-
associated proteins. To date, a host of such proteins have been
identified [6], and many of them likely play a role in the
organization of transporter containing microdomains. We
can anticipate these studies to provide an ongoing dialogue
between in vitro and in vivo approaches, as the assessment of
protein interaction interfaces in reduced preparations will
likely provide the tools to manipulate these interactions in
the brain. This exercise is far from an ivory tower academic
pursuit. Knowing how transporters achieve an appropriate
membrane microdomain localization will likely identify new
opportunities to influence synaptic transmission to improve
human health, and also to understand how alterations in other
proteins can result in changes in neurotransmitter dynamics.
Two examples illustrate the point. Cremona and colleagues
recently demonstrated that the interactions of DAT proteins
with the membrane microdomain-associated protein flotillin 1
is required for AMPH-inducedDA efflux [17], suggesting that
we are likely to learn much about the actions of
psychostimulants through a better understanding of these
domains and the proteins they contain. Finally, we recently
demonstrated that DAT proteins expressing an ADHD-
associated DAT mutation (615C) fail to target properly to
GM1-rich membrane microdomains and as a result display
abnormal trafficking kinetics and modulation by PKC and
AMPH. These examples, interestingly enough, connected by
the actions of AMPH, underscore the importance of biogenic
amine transporters being at the right place, at the right time.
Transporter activity states
Neurotransmitter enzymes and receptors display regulated
shifts between conformational states that in turn functional
capabilities, be it an alteration in neurotransmitter synthesis or
probability of neurotransmitter binding triggering a down-
stream signal. For neurotransmitter transporters, conforma-
tional changes are often only considered as the rearrangements
of the “open-out, open-in” states that describe, at a gross level,
the transport cycle. However, the occurrence of stable changes
in transporter conformation that lead to altered substrate af-
finity or the probability of transport are also beginning to be
appreciated. We became interested in the possibility of regu-
latory transporter “activation” when we discovered that insu-
lin, via a p38 MAPK-linked pathway, could rapidly enhance
NET activity in SK-N-SH cells without elevating total trans-
porter protein levels or transporter surface expression [4].
Interestingly, p38 MAPK-linked pathways can also rapidly
enhance transport activity of SERT proteins in a trafficking-
independent manner [92], a pathway that we now know can be
induced in vitro by inflammatory cytokines (e.g., IL-1β,
TNFα) in vitro and by peripheral immune system activation
in vivo [94]. Kinetic studies indicate that these changes in
activity derive from a stable shift of transporters between low
and high-affinity conformations. What parts of transporter
structure reorient under these conditions and how such con-
formations are normally constrained and mobilized are of
critical importance as wemove forward. In the SERT quantum
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dot studies noted above [15], we demonstrated that elevated
SERT activity triggered by IL-1β is associated with an in-
creased lateral mobility of transporters, though these mole-
cules still remain lodged within GM1-enriched membrane
microdomains (Fig. 4). As we found that changes in both
SERT activity and mobility could be induced by
cytochalasin-induced disruption of the actin cytoskeleton or
by membrane permeant peptides that mimic the SERT C-
terminus, we proposed that constraints on transporter lateral
mobility and constraints on transporter structural conforma-
tions are different features of the same process, the tethering of
SERT to the cytoskeleton by C-terminal-associated proteins.
The studies note above suggest that biogenic amine
transporter-associated proteins not only chaperone trans-
porters from biosynthetic compartments to the cell surface
and dictate their membrane trafficking, but also establish the
permissible range of conformations that dictate substrate af-
finity and transport rates. Since some protein associations
likely play roles in trafficking, localization and activity,
methods must be implemented that can separate these pro-
cesses, physically and temporally, if we are to capture the full
extent of transporter regulation. Detached patch recording
methods have provided single molecule regulation of confor-
mational states of ion channels and the demonstration of
electrical signatures of biogenic amine transporter-associated
channel states offers a similar opportunity [33, 34]. One
example of the power of this approach comes from the dem-
onstration that the SNARE protein syntaxin 1A can alter NET
function in a trafficking-independent manner via the elimina-
tion of NE-gated NET channel activity [77]. As with other
aspects of transporter regulation, observations of biased alter-
ation of transporter conformation from in vitro observations in
reduced preparations need to be demonstrated to support the
capacity for neurotransmitter uptake in vivo. This author may
have his biases, but unabashedly admits that they derive from
the many fruitful associations that sometimes constrain but
more often enhance his activity.
The SLC6 transporter family: gene variants and mouse
genetic models relevant to neuropsychiatric disorders
and their treatment (Dennis L. Murphy)
By far, the greatest number of studies examining transporters
in the SLC6 family related to neuropsychiatric disorders have
focused on polymorphisms or rare variants in the serotonin
transporter gene (SLC6A4) and its protein, SERT, the dopa-
mine transporter gene (SLC6A3) and its protein, DAT, plus a
few studies of the norepinephrine transporter gene (SLC6A2)
and the GABA and glycine transporter genes. Thus, this brief
review covers only major examples of genetic variants, phar-
macological targets and a few associated mouse genetic
models that provide useful insights into behavioral and phys-
iological consequences of alterations in SLC6 transporters.
New reviews and major papers are cited; a more complete list
of references in an annotated version of this review is available
upon request. Some overall perspectives and ideas for future
studies are also noted in the “Conclusion”.
SLC6A4 (Chromosome 17.11–12) encodes the single SERT
with characteristic 12 transmembrane-spanning segments. A
promoter region length variant, 5HTTLPR and two closely
associated SNPs (rs25531, rs25532), alter the expression,
trafficking and function of SERT. These variants have been
Fig. 4 Model for SERT-cytoskeletal interactions dictating cell surface
transporter regulation. In the resting state, SERT is present in two com-
partments, one that permits free diffusion in the membrane (left), and a
second compartment that represents confinement to membrane microdo-
mains (center) where transporters are immobilized by cytoskeleton-asso-
ciated proteins (middle). When cytoskeleton- associated constraints are
relaxed in response to PKG/IL-1β/p38 MAPK activation (or through
actin destabilizers or C-SERT peptide treatments), SERT remains
confined to membrane microdomains (right), though now transporters
can adopt conformations that favor increased transport activity. Question
mark overlying transitions into and out of membrane microdomains
denotes the possibility that such movements could also play a role in
SERT regulation, though they are not features of the PKG and p38
MAPK-dependent SERT regulation detected in the current study.
Adapted from Chang et al. [15]
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most clearly associated with anxiety-related traits, anxiety
disorders (especially obsessive–compulsive disorder [OCD])
and perhaps depression, bipolar disorder, ADHD, and
Tourette’s disorder (TD). An intron 2 VNTR shows evidence
of functional consequences in model systems; only scattered
clinical studies suggest an association with depressive disor-
ders. Several rare SERT variants (e.g., I425V, which is most
closely associated with OCD and TD) and a cluster of rare
SNPs associated with autism are all gain-of-function variants
affecting serotonin uptake and SERT regulation in cell culture
systems (reviews: [39, 54]).
Selective serotonin reuptake inhibitors (SSRIs, which are
inhibitors at the SERT transport site) are FDA approved as
antidepressants and anti-anxiety disorder agents. Studies of
the crystal structure of LeuT a bacterial homolog of SERT,
DAT, and NET [60, 83, 91] indicate that antidepressants
occupy the substrate site of the transporters, preventing con-
formational changes and thus preventing substrate transport.
SRIs (including clomipramine) are the only approved class of
drugs for OCD, a disorder non-responsive to other conven-
tional anxiolytic agents that act via gabaergic and related
systems (e.g., diazepam and its congeners). Some mixed
evidence suggests that therapeutic responses—but more
prominently side effects from SSRIs such as diarrhea—are
related to the SERT promoter region polymorphisms [40].
SERT knockout mice (SERT−/−mice) and SERT deficient
(+/− mice) have 5- to 9-fold increases in microdialysis-
measured brain ECF serotonin, and a variable reduction ac-
cording to brain region in serotonin content, associated with
increased anxiety-related behaviors, exaggerated stress re-
sponsiveness, reduced locomotor activity and approximately
fifty-plus related brain and peripheral phenotypic abnormali-
ties. SERT knockout rats exhibit highly parallel findings to
those found in SERT knockout mice. Transgenic SERT over-
expressing mice show reduced anxiety and related behaviors
and other reversed phenomena including serotonin receptor
changes compared to SERT-deficient mice (reviews: [41, 55]).
SLC6A3 (Chromosome 5p15.33) encodes the single DAT.
Genetic studies have indicated that common variants in DAT
may be associated with ADHD, bipolar disorder as well as
substance abuse, including cigarette smoking [OMIN
126455]. A rare functional DAT variant, A559V, was found
in two ADHD-affected siblings and also in a patient with
bipolar disorder; efflux rates of dopamine induced by amphet-
amine comprise the most prominent functional alteration as-
sociated with the DAT A559V mutation. Two other loss-of-
function mutations, DAT P395L and L368Q, were found
associated with a Mendelian recessive disorder, infantile par-
kinsonian dystonia, characterized by rigidity, in two indepen-
dent families [44]. The partially selective DAT inhibitor,
methylphenidate, is the most widely prescribed anti-ADHD
agent, although d-amphetamine (which is an inhibitor of DAT,
NET, and SERT) is also used in ADHD treatment. DAT
knock-out mice exhibit very prominent hyperactivity, reduced
body size and weight, with 5-fold increases in striatal ECF
dopamine, accompanied by markedly reduced brain tissue
dopamine content. Other behavioral features of these mice
that resemble both some ADHD-like as well as OCD-and
autism-like phenomena include stereotypic behavior, reduced
habituation to novelty and some cognitive deficits [31]. The
hyperactivity of the DAT knockout mice can be suppressed by
d-amphetamine (which is a locomotor stimulant in wild-type
mice). Other genetic mouse models of partial DAT deficiency
and of DATover-expression have been less well-characterized
but suggest behavioral and biochemical alterations in the same
domains as those found in DAT knockout mice.
SLC6A2 (Chromosome 16q12.2) encodes the norepinephrine
transporter, NET. No common variants in SLC6A2 associated
with neuropsychiatric disorders have been identified. The most
prominent rare variant occurs in exon 9 yielding NET A457P,
which was reported in a family constellation consisting of five
siblings and their mother, all of whom suffered from orthostatic
intolerance (an abnormal increase in heart rate and plasma
norepinephrine upon standing, along with clinical symptoms
of faintness and dizziness). The mutation leads to an almost
complete loss of NET function, with greatly reduced NET
surface expression. NET knockout mice have reduced locomo-
tor activity in a novel environment together with elevated heart
rates and increased blood pressure in response to activating
stimuli. Like SERT and DAT knockout mice, the NET knock-
outs have increased ECF transmitter concentrations (here, NE)
as measured by microdialysis, accompanied by markedly re-
duced tissue NE [32].
SLC6A5 Encodes the glycine transporter, GLYT2. Rare vari-
ants in this gene (frame shift or other mutations) have been
identified in several different pedigrees with excessive startle
responses (most commonly an autosomal recessive disorder,
termed hyperekplexia). GLYT2 is the presynaptic neuronal
glycine transporter and GLYT1 is the glial glycine transporter.
Glycine is a major inhibitory neurotransmitter in the brainstem
and spinal cord, regulating strychnine-sensitive glycine recep-
tors. Glycine also acts as a co-agonist with glutamate at
NMDA receptors. GLYT1 and GLYT2 knockout mice both
die shortly after birth.
SLC6A1 Encodes the GABA transporter, GAT1. Only indi-
rect human gene and post-mortem studies have raised the
question of SLC6A1’s involvement in anxiety disorders,
schizophrenia and seizure disorders. GAT1 knockout mice
exhibited a seizure disorder, tremor and abnormal locomotor
functions, although another study reported reduced anxiety-
like, depression-like and aggression-related behaviors, associ-
ated with elevated brain GABA concentrations.
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Conclusion
Perspectives and ideas for future studies Perhaps most strik-
ing in this review is the consistency between genetic knockout
mice models (and a few transgenic, over-expressing mouse
lines) with expected consequences from transporter alterations
found in biochemical and behavioral evaluations.
Biochemically, transporter deficiencies lead to excess ECF
neurotransmitter concentrations associated with reduced brain
and other tissue concentrations of the relevant transmitter.
Behavioral consequences are consistent with what had previ-
ously been observed with pharmacological manipulations of
tissue homeostasis and receptors for each of these transmitters.
Human genetics findings to date, particularly those associated
with rare coding change variants, also seem to follow antici-
pated phenotypes. However, the field has to be cautious of
“looking under the lamppost for lost keys” phenomena, as in
many cases clinical evaluations are limited in scope.
Nonetheless, the general findings, assuming support continues
from studies of genetic mouse, other rodent and non-human
primate models, bodes well for understanding human disor-
ders. Current studies reviewed here certainly emphasize the
importance of SLC6 transporters in multiple neuropsychiatric
disorders as well as their treatment. Many study opportunities
remain. The field is still searching for genetic and other
biomarkers that might prove more useful than clinical features
alone for the future goal of personalized medical diagnoses
and treatment of neuropsychiatric disorders.
Clinical heterogeneity, evident in major neuropsychiatric
disorders such as OCD, bipolar disorder, and others, repre-
sents in clinical featuresmultiple kinds of problems. Likewise,
genetic heterogeneity, for example evident in variants within
genes (e.g., SLC6A4), gene×gene, gene×environment and
epigenetic variability, compounds assessment of “genetically
complex” disorders. Taken together, this leaves us with much
to unravel in the SLC6 scientific world.
While some current state-of-the-art GWAS (genome-wide
association studies) plus GWAS metanalyses have led to
“hits” within likely genes relevant to neuropsychiatric disor-
ders, other major genome-wide single “hits” have been in
unlikely genes not resolvable by pathway or network analyses
(e.g.,, [70]). While the latter two approaches are predicted to
prove highly valuable, they do not help with the not uncom-
mon result of a “hit” in a large intergenic area. While this
author is an avid participant in biomarker, GWAS and the
network pathway study of genes, this complexity also sug-
gests seizing upon the opportunities presented by rare genes
found in maybe only a few pedigrees or 1–2 % of individuals
in case–control studies of neuropsychiatric disorders.
Intensive investigations of new functional rare variants using
all molecular, neurochemical, electrophysiological techniques
and transgenic mouse models that can mimic the variant’s
consequences in vivo may point towards otherwise
unforeseen areas for investigating related patient groups or
new pathways. Indeed, studies this year have suggested new
ideas for SLC6 investigators, for example, genes previously
identified as “oncogenes” have now been preferentially found
in autism patient samples vs. controls [78]. Likewise, a net-
work of 50 embryonic developmental genes has been found
expressed preferentially in the prefrontal cortex of adult
schizophrenic patients versus control brains [38].
Additionally, a recent paper described a surprising overlap of
associated genes across five neuropsychiatric disorders, way
beyond traditional diagnostic boundaries [47]. Such new co-
nundrums around every corner will continue to challenge
transporter genetics and biology.
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